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Abstract 
Background: ABO blood groups have previously been associated with cardiovascular disease (CVD) in the general 
population. This study aimed to investigate the potential relationship between ABO blood groups and CVD in indi‑
viduals with type 1 diabetes according to diabetic nephropathy (DN) status.
Methods: Adults with type 1 diabetes (4531 individuals) from the FinnDiane Study were evaluated. DN was deter‑
mined by two out of three measurements of urinary albumin excretion rate. Albuminuria was defined as an excretion 
rate above 20 µg/min. CVD events were identified by linking the data with the Finnish Care Register for Health Care 
and the Finnish Cause of Death Register. Follow‑up ranged from the baseline visit until a CVD event, death or the 
end of 2017. The impact of ABO blood groups on CVD risk was estimated by multivariable Cox‑regression analyses 
adjusted for traditional risk factors.
Results: At baseline, the median age was 38.5 (IQR 29.2–47.9) years, 47.5% were female and median duration of 
diabetes was 20.9 (11.4–30.7) years. There were 893 incident ischemic heart disease (IHD) events, 301 ischemic strokes 
(IS), and 415 peripheral artery disease (PAD) events during a median follow up of 16.5 (IQR 12.8–18.6) years. The A 
blood group showed the highest risk of IHD versus the O blood group, when microalbuminuria was present. Compar‑
ing the population with microalbuminuria with those with normoalbuminuria, only the A blood group elevated the 
risk of IHD. This increased risk was neither explained by the FUT2 secretor phenotype nor by the A‑genotype distribu‑
tion. The risk of IS or PAD was no different among the ABO blood groups regardless of diabetic nephropathy stage.
Conclusion: The A blood group is a risk factor for IHD in individuals with type 1 diabetes and microalbuminuria.
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Background
Cardiovascular disease (CVD) is the major cause of death 
among people with diabetes worldwide and the ABO 
blood groups have been associated with CVD in several 
studies [1–3]. The first time the ABO blood groups were 
shown to be associated with CVD was in 1962 [4] when 
the A and B blood groups were linked to ischemic heart 
disease (IHD). Recently, it was described that ABO blood 
groups are associated with increased cardiovascular risk 
in individuals with familial hypercholesterolemia [5]. The 
majority of previous studies have indicated that the O 
blood group confers the lowest risk of thrombotic events, 
although the group with the highest risk is still contro-
versial and depending on the studied population [1–3, 6].
The reasons why the ABO blood group is a risk fac-
tor of CVD is still under investigation. ABO antigens are 
not expressed only on the surface of red blood cells but 
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also on epithelial and endothelial cells, T-cells, B-cells 
and platelets [8]. These antigens might also be found in 
the circulation and body secretions, if the individual has 
the FUT2 gene secretor phenotype [8]. The interaction 
between ABO blood antigens and adhesion molecules, 
such as the soluble InterCellular Adhesion Molecule 1 
(sICAM-1), may differ depending on the A blood group 
subtypes A1 or A2, which interferes with the leucocyte 
endothelium adhesion [9]. Different levels of the von 
Willebrand factor (vWF) [10] and HDL-cholesterol con-
centrations [11] have also been suggested to explain the 
relationship between ABO blood groups and CVD risk.
CVD is a major cause of premature mortality in indi-
viduals with type 1 diabetes, especially if diabetic 
nephropathy (DN) is present [12–14]. Acute diabetic 
complications drive the mortality rate during the first 
years of living with type 1 diabetes, but IHD becomes the 
main cause of premature mortality of those with longer 
duration of diabetes [15]. Although there are several well-
known CVD risk factors in type 1 diabetes, the potential 
impact of the ABO blood groups on this risk has never 
been studied in this population. This study therefore 
aimed to explore this unanswered question taking differ-
ent DN stages into account.
Methods
Research design
This is an observational prospective study to evaluate 
the relationship between ABO blood groups and CVD 
in type 1 diabetes according to DN stage as part of the 
ongoing Finnish Diabetic Nephropathy (FinnDiane) 
Study, which is a nationwide, prospective, multicenter 
study aiming to identify risk factors for type 1 diabetes 
complications. The CVD risk of ABO blood groups was 
compared according to the various stages of DN.
Study population
The FinnDiane Study has since 1997 recruited and char-
acterized individuals with type 1 diabetes 18  years or 
older from 93 centers across Finland and the recruitment 
of new study participants is still ongoing. This analysis 
included 4531 individuals with type 1 diabetes with uri-
nary albumin excretion rate (UAER) data and informa-
tion on ABO blood groups available. Type 1 diabetes 
was defined as age at onset of diabetes under 40  years 
and permanent insulin treatment initiated within a year 
from the diabetes diagnosis. The study protocol followed 
the principles of the Declaration of Helsinki as revised in 
2000 and was approved by the Ethical Committee of Hel-
sinki and Uusimaa Hospital District. Written informed 
consents were obtained from each FinnDiane partici-
pant. The baseline visit occurred between the years 1997 
and 2015 and at which the participants underwent a 
thorough clinical examination, blood and urine samples 
were collected and several questionnaires including spe-
cific questions about lifestyle habits were completed by 
the participants.
DN stage
The stage of DN was based on the individuals’ urinary 
albumin excretion rate (UAER) from timed overnight 
and 24  h urine (mg/24  h) collections. Normoalbuminu-
ria was defined as a UAER < 20 µg/min or < 30 mg/24 h in 
at least two out of three urine samples. Microalbuminu-
ria was defined as UAER ≥ 20 and < 200  µg/min or ≥ 30 
and < 300 mg/24 h, macroalbuminuria as UAER ≥ 200 µg/
min or ≥ 300 mg/24 h and end-stage renal disease (ESRD) 
as dialysis or kidney transplantation.
ABO blood groups
The ABO blood groups were determined based on 
genetic variants coding for or tagging the O (rs8176719 
deletion allele), B (rs8176746 A allele), and A (rs8176747 
G allele) groups [16]. The A1 versus A2 subgroup was 
defined based on the rs8176750 C allele [17]. Secretor 
status was defined based on the FUT2 rs601338 AG/GG 
genotypes [18]. Genotyping was done with Human Core 
Exome Bead Chips 12–1.0, 12–1.1 or 24–1.0 (Illumina, 
San Diego, CA, USA), with genotype imputation using 
the 1000 genomes reference panel, as described ear-
lier [19]. The rs8176746 was directly genotyped, and the 
other variants were imputed with high quality  (r2 ≥ 1.0); 
most likely genotypes were used for the imputed variants.
CVD
With CVD events we refer to IHD, ischemic stroke (IS) 
and peripheral arterial disease (PAD). The correspond-
ing international classification of disease (ICD) codes are 
listed in the Additional file 1: table S1. CVD events were 
identified by linking the data with the Finnish Care Regis-
ter for Health Care and the Finnish Cause of Death Reg-
ister. Participants that had had a CVD event before the 
baseline visit were excluded. The follow-up period ranged 
from the baseline visit until the occurrence of the first 
CVD event, death or the end of 2017.
Utilization of antibiotic drugs
We used the Finnish Drug Prescription Register of anti-
biotic purchase per person per year to investigate the dis-
tribution of the number of infections per person per year 
among the ABO blood groups.
Statistical analysis
Data on categorical variables are presented as frequen-
cies, while continuous variables are shown as means 
(± standard deviation, SD) for normally distributed 
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values and variables with skewed distribution as medians 
(interquartile ranges, IQR). Between-group comparisons 
were performed with Chi squared test, ANOVA for nor-
mally distributed continuous variables, otherwise by the 
Kruskal–Wallis test.
The impact of the ABO blood groups on CVD risk 
was estimated by multivariable Cox-regression analyses 
adjusted for the following traditional risk factors: age at 
diabetes diagnosis, body mass index (BMI), duration of 
diabetes, systolic blood pressure (SBP), HDL cholesterol, 
triglycerides,  HbA1c, sex, severe diabetic retinopathy 
(defined as laser treatment) and history of smoking. 
Interaction between ABO blood groups and DN sta-
tus was tested and since it was significant, the analyses 
were conducted separately for each DN group. However, 
the interaction between the ABO blood groups and sex 
was not significant and therefore these analyses were 
conducted by pooling men and women. The assump-
tion of the proportional hazards was tested by Schoen-
feld residuals against time and testing a non-zero slope 
Table 1 Baseline characteristics according to ABO blood groups
Data are given as mean ± SD or median and interquartile range
HbA1c glycated hemoglobin, Hs-CRP high-sensitivity C-reactive protein, DN diabetic nephropathy, ACE angiotensin-converting enzyme inhibitor, ARB angiotensin 
receptor blockers, HDL high-density lipoprotein, FUT2 fucosyltransferase-2, IHD ischemic heart disease
p value refers to ANOVA, Kruskal–Wallis test or χ2-test adjusted for age at baseline when applicable. Comparisons are made among ABO blood groups
O A B AB p
n = 1333 (29.4%) n = 2012 (44.4%) n = 796 (17.6%) n = 390 (8.6%) value
Sex (female  %) 46.5 47.5 48.0 50.3 0.62
Age (years) 38.0 (29.2–47.5) 38.2 (29.2–47.8) 39.2 (29.1–48.4) 39.3 (29.0–48.5) 0.81
Duration of diabetes (years) 21.5 (11.3–30.8) 20.4 (11.4–30.3) 21.3 (12.0–30.7) 21.0 (11.2–32.7) 0.47
HbA1c (%) 8.4 ± 1.5 8.4 ± 1.5 8.4 ± 1.5 8.3 ± 1.4 0.46
Smoking history (%) 46.4 47.5 47.4 46.9 0.95
Body Mass Index (kg/m2) 25.1 ± 3.5 25.1 ± 3.8 25.0 ± 3.5 25.0 ± 3.9 0.81
Waist‑to‑hip ratio 0.87 ± 0.08 0.87 ± 0.09 0.87 ± 0.09 0.87 ± 0.08 0.71
Systolic blood pressure (mmHg) 134 ± 18 135 ± 19 134 ± 18 135. ± 20 0.44
Diastolic blood pressure (mmHg) 80 ± 10 80 ± 10 80 ± 10 79 ± 10 0.74
Total cholesterol (mmol/l) 4.90 ± 0.99 4.95 ± 1.01 4.87 ± 0.93 4.95 ± 0.95 0.17
HDL cholesterol (mmol/l) 1.32 ± 0.38 1.33 ± 0.39 1.35 ± 0.40 1.36 ± 0.41 0.25
Triglycerides (mmol/l) 1.06 (0.78–1.51) 1.03 (0.78–1.52) 1.01 (0.77–1.45) 1.04 (0.75–1.40) 0.16
Hs‑CRP (mg/l) 4.5 ± 9.4 4.6 ± 9.4 4.2 ± 8.5 4.7 ± 9.0 0.64
DN groups 0.42
Normoalbuminuria (n,  %) 862 (64.7) 1311 (65.2) 505 (63.4) 253 (64.9)
Microalbuminuria (n,  %) 178 (13.4) 251 (12.5) 109 (13.7) 44 (11.3)
Macroalbuminuria (n,  %) 199 (14.9) 272 (13.5) 124 (15.6) 55 (14.1)
ESRD (n,  %) 94 (7.0) 178 (8.8) 58 (7.3) 38 (9.7)
Laser treatment (%) 34.7 31.9 35.2 34.3 0.22
Lipid lowering therapy (%) 13.0 14.6 11.6 15.0 0.36
Blood Pressure lowering therapy (%) 38.8 39.3 39.0 40.0 0.98
ACE/ARB users (%) 30.3 31.0 30.7 30.5 0.98
FUT2 Secretor (%) 81.4 82.7 82.4 83.5 0.72
Antibiotic purchases per person year 0.62 (0.30–1.46) 0.63 (0.28–1.33) 0.59 (0.26–1.34) 0.60 (0.28–1.30) 0.90
IHD (n,  %) 82 (6.2) 132 (6.6) 49 (6.2) 30 (7.7) 0.50
Socioeconomic status
 Blue collar  worker (%) 56.9 58.0 60.7 57.0 0.48
 White collar  worker (%) 32.6 30.2 30.4 32.3
 Others (%) 3.6 4.3 2.8 3.2
 Not known (%) 6.9 7.5 6.1 7.6
 Alcohol consumption (g/week) 48.0 (24.0–84.0) 48.0 (24.0–84.0) 42.0 (24.0–84.0) 36.0 (24.0–84.0) 0.06
 Abstainers (%) 26.5 27.1 26.8 26.7 0.18
 Missing data (%) 9.3 9.8 9.8 6.2 0.76
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by including time-covariate interactions. In case the 
assumption did not hold the interaction between the 
covariate and time was added to the final model. All anal-
yses were performed with Statistical Analysis System ver-
sion 9.4 (SAS Institute, Cary, NC, USA).
Results
At baseline, the median age was 38.5 (IQR 29.2–47.9) 
years, 47.5% were female and the median duration of 
diabetes was 20.9 (11.4–30.7) years. There were 893 
incident IHD events, 301 IS and 415 PAD events dur-
ing 62,326 person-years for IHD, 68,137 for IS and 
67,118 for PAD during a median follow up of 16.5 (IQR 
12.8–18.6) years.
Baseline characteristics such as the prevalence of IHD, 
FUT2 secretor phenotype, number of antibiotic pur-
chases per person per year, serum hs-CRP level, DN 
stages and other well-known CVD risk factors were no 
different between the ABO blood groups (Table 1). ABO 
genotypes were also equally distributed according to the 
DN stages (Fig. 1).
Among individuals with microalbuminuria, those 
with the A blood group showed the highest risk of IHD 
compared to those with O blood group (HR 1.93, CI 
95% 1.24–3.00) (Fig. 2). A similar result was seen in the 
microalbuminuric group comparing the non-O blood 
group (A, B and AB) with the O blood-group (HR 1.81, 
CI 95% 1.15–2.84) (Additional file 1: Table S2). There was 
no difference in the risk of IHD between the ABO blood 
groups at any of the other DN stages (Fig.  2 and Addi-
tional file 1: Table S2).
Comparing individuals with microalbuminuria to 
those with normoalbuminuria, only the A blood group 
showed a greater risk of IHD (HR 1.94, CI 95% 1.41–2.67, 
p < 000.1) (Fig. 3).
Among the individuals with the A blood group, the 
incidence of IHD events (29.3% vs 10.9%, p < 0.0001), 
levels of serum high sensitivity C-reactive protein (hs-
CRP) (2.51 mg/l vs 1.71 mg/l, p < 0.001) and the number 
of antibiotic purchase per person per year (0.78 vs 0.47, 
p < 0.001) were greater in the individuals with microal-
buminuria compared to those with normalbuminuria, 
although there was no difference in the prevalence of 
FUT2 secretor phenotype (p = 0.82), nor the A1/A2 sub-
type distribution (p = 0.87) (Additional file 1: Table S3).
The risk of IS and PAD was no different among the 
ABO blood groups, regardless of DN status (Additional 
file 1: Tables S4, S5).
Discussion
This is the first study to show that the A blood group is 
a risk factor for IHD in a large cohort of individuals with 
type 1 diabetes and microalbuminuria. The risk was 93% 
higher compared to the risk in those with the O blood 
group at the same DN stage. The risk of IHD was also 
81% higher when the non-O blood group carriers were 
compared to the O blood group in those with microal-
buminuria. Of note, the risk of the non-O blood group 
p=0.58, no difference in the distribution according to DN stages.
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Page 5 of 9Parente et al. Cardiovasc Diabetol           (2020) 19:68  
was driven by the high risk of the A blood group. Fur-
thermore, individuals with microalbuminuria and the A 
blood group had a 94% higher risk of IHD compared to 
those with normoalbuminuria.
Although the O blood group has often been considered 
as the reference group with the lowest risk of ischemic 
CVD, the blood group with the highest risk has also var-
ied depending on the studied population. Whether this is 
due to ethnical differences is not known. On one hand, 
a cross-sectional study with 299 individuals from Africa 
showed that the A blood group is the one with the high-
est risk of ischemic CVD, defined as coronary artery dis-
ease, myocardial infarction or IS [20]. On the other hand, 
a study on 64.686 blood donors from Canada showed 
that the AB blood group is the one carrying the high-
est risk of hospitalization or death due to thrombogenic 
events such as coronary, cerebrovascular or peripheral 
disease [21]. A study from Italy on a small cohort of 249 
blood donors showed that the non-O blood group was 
the group with the highest risk of cardiovascular events 
[22], and similar results were obtained from a larger 
study from Sweden and Denmark with 1.5 million blood 
donors showing that individuals with the non-O blood 
group had higher incidence of both venous and arterial 
thromboembolic events than the O blood group [23]. 
Finally, a meta-analysis also described the A blood-group 
O-blood-group is the reference group 1.0. HR: hazard ratio; CI: confidence interval; 
Analysis were adjusted for age at diabetes diagnosis, duration of diabetes, body mass 
index, systolic blood pressure, HDL cholesterol, triglycerides, HbA1c, sex, severe 
diabetic retinopathy (laser treatment) and smoking. *p < 0.05 compared to the reference 
group.
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A:   0.94 (0.72-1.23)
B:   1.00 (0.71-1.41)
AB: 1.41 (0.94-2.1)
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[2] and the non-O blood group [2, 3] as the highest risk 
groups for coronary artery disease, data that are in con-
cordance with our results. However, the question arises, 
why does the A blood group in our and other populations 
confer an increased risk of IHD, and why is this risk par-
ticularly seen in those individuals with type 1 diabetes 
and microalbuminuria.
ABO genotype and CVD
In order to answer this question we analyzed the ABO 
genotype distribution, especially the A1 and A2, among 
the different DN groups, since it has been described that 
the A1 subtype confers higher thrombogenic risk than 
the A2 subtype [23, 24], but we found no difference in 
the genotype distribution in our population. It has been 
suggested that the A blood group antigen can bind to 
endothelial cells and thereby contribute to cytoadher-
ence, and the mechanism might involve antigen glyco-
sylation that interacts with the p-selectin/ICAM-1 [25]. 
In this respect, the risk difference among the A blood 
group individuals could possibly be explained by lower 
levels of sICAM-1 in the A1 compared to the A2 car-
riers [9]. Unfortunately, we did not have access to any 
sICAM-1 measurements from our population.
FUT2 secretor phenotype and CVD
We also evaluated the frequency of FUT2 secretors 
and non-secretors, in order to explore the interactions 
HR: hazard ratio; CI: confidence interval; Analyses were adjusted for age at diabetes diagnosis, 
duration of diabetes, BMI, systolic blood pressure, HDL cholesterol, triglycerides, HbA1c, sex, 
severe diabetic retinopathy (laser treatment) and smoking.
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between the ABO antigens and the endothelial adhesion 
molecules. It has been suggested that only people with 
a functional FUT2 gene can secrete ABO antigens into 
the body fluids, a phenomenon characterizing the FUT2 
secretor phenotype [26]. However, we did not find any 
differences in the distribution of FUT2 secretor pheno-
type among the different ABO blood groups nor between 
the A blood group individuals with normo- or microal-
buminuria in our population.
Infections and CVD
It is of note that there is a clear association between bac-
terial infections and the risk of CVD [27, 28], and it is also 
well-known that bacterial infections have both a direct 
and an indirect effect on the atherosclerotic process 
[27], an inflammatory condition that starts with lesions 
and dysfunction of the endothelium [28]. As previous 
data from our group showed that individuals with type 
1 diabetes have a higher risk of bacterial infections [29], 
thus,  we explored whether this increased risk of infec-
tions may be due to the ABO blood group and whether 
the ABO blood group could also have an impact on the 
risk of CVD in this population. Although there were no 
differences in the prevalence of infections among the 
various blood groups (Table 1), the individuals with the 
A blood group and microalbuminuria had a higher inci-
dence of IHD events, higher hs-CRP levels and a higher 
number of antibiotic purchases per person per year com-
pared to the individuals with normoalbuminuria with 
the same blood group. Thus, the inflammation/infection 
could be a possible mediator of this relationship between 
the A blood group, microalbuminuria and IHD. However, 
we do not know how inflammation after or during a bac-
terial infection, or how the microalbuminuric state might 
facilitate adhesion of the A-antigen to the endothelium.
Lipids and CVD
Given the well-known associations between the lipids 
and CVD, we also investigated the distribution of total 
cholesterol, HDL-cholesterol and triglycerides among the 
ABO blood groups. However, there were no differences 
between the groups. In contrast, a Chinese study with 
6476 individuals, showed that about 10% of the effect of 
the non-O blood group on the risk of coronary artery dis-
ease was mediated by its influence on LDL-cholesterol 
[30]. In an Indian study, the AB blood group was associ-
ated with high concentrations of HDL-cholesterol, while 
the O blood group was associated with low concentra-
tions [11]. Besides these ethnical differences, there might 
be additional factors involved in type 1 diabetes such as 
proteomic alterations of the HDL-cholesterol [31] and a 
higher prevalence of coronary atherosclerosis compared 
to controls [32] that might increase the risk of CVD. 
Whether the ABO blood groups may have an impact on 
such alterations of the HDL-cholesterol molecules is not 
known.
Other factors and CVD
There are also other factors that might interact with the 
ABO blood group antigens and thereby modulate the risk 
of ischemic CVD. For instance, it is well-known that the 
non-O blood group is associated with lower clearance 
of the vWF. Reduced clearance of vWF leads to a subse-
quent elevation of its plasma concentrations, which in 
turn enhances the chance of thrombogenic events [3, 10, 
33]. Other explanations for the high risk of CVD in the 
non-O blood group could be the size of the platelets [34], 
the interaction between the red blood cell surface anti-
gens (A, B, AB) with sICAM [3, 9, 25], p-selectin [25], 
E-selectin [35, 36] or plasma glycine [37, 38]. Unfortu-
nately, none of these factors were measured in the pre-
sent study.
ABO blood groups and the risk of IS and PAD
In our analysis, the ABO blood groups were neither a rel-
evant risk factor for IS nor PAD. Conversely, the MESA 
study showed that the A blood group was associated with 
a greater risk of PAD in African Americans, although it 
was not significant in Chinese, non-Hispanic white or 
Hispanic Americans [39]. Since our study was performed 
in a Caucasian Finnish population, race/ethnicity factors 
might be involved in the observed differences. Regarding 
the risk of IS, our results are similar to a Canadian study 
[21] in which any ABO blood group was a risk factor for 
hospitalization or death because of cerebrovascular dis-
ease. In the Canadian study, the ABO blood group was 
a risk factor for cerebrovascular disease only, when it 
was analyzed together with coronary artery disease. The 
smaller number of incident IS (n = 301) compared to the 
number of IHD (n = 893) could be a reason, why we did 
not detect any statistically significant difference in the IS 
risk.
Notably, in this study the ABO blood groups had no 
impact on CVD risk in individuals with advanced kidney 
disease, such as macroalbuminuria or ESRD. It is possible 
that advanced kidney disease in itself is such a strong risk 
factor for CVD that it might overrule any other thrombo-
genic risk factor, for instance the ABO blood groups.
Limitations and strengths
A clear limitation is that we did not have information 
on vWF, sICAM-1, LFA-1, E-selectin, p-selectin, plasma 
glycine or platelet size that could have helped us further 
explore the relationship between the ABO blood groups 
and the thrombogenic risk. Another limitation is the 
small number of individuals in the AB blood group that 
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limited our possibility to draw any conclusions regarding 
the CVD risk of this group.
Albeit these limitations, the strength of this study is its 
novelty to demonstrate that the A blood group is a risk 
factor for IHD in a large cohort of individuals with type 1 
diabetes and microalbuminuria, a group that already car-
ries a high CVD risk.
Conclusion
The A blood group is an additional risk factor for IHD 
in individuals with type 1 diabetes and microalbuminu-
ria, independently of the traditional CVD risk factors. In 
contrast, the ABO blood groups do not confer additional 
risk regarding IS or PAD in individuals with type 1 dia-
betes, regardless of the DN stage. Our results motivate 
further studies to elucidate the precise mechanism of the 
relationship between the A blood group, microalbuminu-
ria and IHD. From a clinical perspective, our results raise 
the question, whether the ABO blood groups should 
be considered as an additional risk factor when CVD 
risk is assessed in individuals with type 1 diabetes and 
microalbuminuria.
Supplementary information
Supplementary information accompanies this paper at https ://doi.
org/10.1186/s1293 3‑020‑01038 ‑z.
 Additional file 1: Table S1. Specific codes used for the cardiovascular 
outcomes from the relevant registries.Table S2. IHD risk of ABO blood 
groups stratified by nephropathy stages. Table S3. Comparison between 
individuals with normo and microalbuminuria with A‑blood‑group. 
Table S4. Ischemic stroke risk of ABO blood groups stratified by nephrop‑
athy stages. Table S5. Peripheral artery disease risk of ABO blood groups 
stratified by nephropathy stages. Table S6. List of physicians and nurses 
at each of the FinnDiane centers participating in patient recruitment and 
characterization.
Abbreviations
CVD: Cardiovascular disease; IHD: Ischemic heart disease; IS: Ischemic stroke; 
PAD: Peripheral artery disease; sICAM‑1: Soluble InterCellular Adhesion Mol‑
ecule 1; vWF: von Willebrand factor; DN: Diabetic nephropathy; UAER: Urinary 
albumin excretion rate; ESRD: End‑stage renal disease; SD: Standard deviation; 
IQR: Interquartile ranges; HR: Hazard ratio; CI: Confidence interval; BMI: Body 
mass index; SBP: Systolic blood pressure; CRP: C‑reactive peptide; LFA‑1: Lym‑
phocyte function‑associated antigen‑1; LDL: Low‑density lipoprotein; HDL: 
High‑density lipoprotein.
Acknowledgements
The authors would like to acknowledge all physicians and nurses at each 
FinnDiane center participating in patient recruitment and characterization 
(Additional file 1: Table S6).
Authors’ contributions
EBP and PHG were responsible for study design. EBP was responsible for 
manuscript preparation. VH was responsible for statistical analysis. NS was 
responsible for genetic analysis. PHG, EBP, VH, ML interpreted the results and 
contributed to writing the manuscript. CF contributed to acquisition of the 
data and critical revision of the manuscript. All authors read and approved the 
final manuscript.
Funding
This research was funded by grants from the Folkhälsan Research Founda‑
tion, Academy of Finland (299,200 and 316,664), Wilhelm and Else Stock‑
mann Foundation, Liv och Hälsa Society, Helsinki University Central Hospital 
Research Funds (EVO), Novo Nordisk Foundation (NNF OC0013659), Juvenile 
Diabetes Research Foundation (JDRF, 17‑2013‑7), an EFSD award supported 
by EFSD/Sanofi European Diabetes Research Programme in Macrovascular 
Complications, and Diabetes Research Foundation.
 Availability of data and materials
No data are available. The ethical statement and the informed consent do not 
allow for free data availability.
Ethics approval and consent to participate
The study protocol was in accordance with the principles of the Declaration of 
Helsinki as revised in 2000 and was approved by the Ethical Committee of Hel‑
sinki and Uusimaa Hospital District. Written informed consents were obtained 
from each FinnDiane patient.
Consent for publication
Not applicable.
Competing interests
EBP has received lectures fee from Eli Lilly, Astra Zeneca, Sanofi, Boehringer 
Ingelheim and is an advisory board member of Sanofi. P–H.G. reports receiv‑
ing lecture honorariums from Astellas, Astra Zeneca, Boehringer Ingelheim, 
Eli Lilly, Elo Water, Genzyme, Medscape, MSD, Mundipharma, Novartis, Novo 
Nordisk, PeerVoice, Sanofi, SCIARC and being an advisory board member 
of AbbVie, Astellas, Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Janssen, 
Medscape, MSD, Mundipharma, Novartis, Novo Nordisk, and Sanofi. No other 
potential conflicts of interest relevant to this article were reported.
Author details
1 Folkhälsan Institute of Genetics, Folkhälsan Research Center, Helsinki, Finland. 
2 Faculdade de Ciências Médicas da Santa Casa de São Paulo, São Paulo, Brazil. 
3 Research Program for Clinical and Molecular Metabolism, Faculty of Medi‑
cine, University of Helsinki, Helsinki, Finland. 4 Abdominal Center, Nephrol‑
ogy, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. 
5 National Institute for Health and Welfare, Chronic Disease Prevention Unit, 
Helsinki, Finland. 6 Department of Diabetes, Central Clinical School, Monash 
University, Melbourne, Australia. 
Received: 13 February 2020   Accepted: 9 May 2020
References
 1. Zhang H, Mooney CJ, Reilly MP. ABO blood groups and cardiovascular 
diseases. Int J Vasc Med. 2012;2012:641917.
 2. Chen Z, Yang SH, Xu H, Li JJ. ABO blood group system and the coronary 
artery disease: an updated systematic review and meta‑analysis. Sci Rep. 
2016;6:23250.
 3. He M, Wolpin B, Rexrode K, Manson JE, Rimm E, Hu FB, et al. ABO blood 
group and risk of coronary heart disease in two prospective cohort stud‑
ies. Arterioscler Thromb Vasc Biol. 2012;32(9):2314–20.
 4. Bronte‑Stewart B, Botha MC, Krut LH. ABO blood groups in relation to 
ischaemic heart disease. Br Med J. 1962;1(5293):1646–50.
 5. Paquette M, Dufour R, Baass A. ABO blood group is a cardiovascular 
risk factor in patients with familial hypercholesterolemia. J Clin Lipidol. 
2018;12(2):383.
 6. Gong P, Luo SH, Li XL, Guo YL, Zhu CG, Xu RX, et al. Relation of ABO blood 
groups to the severity of coronary atherosclerosis: an Gensini score 
assessment. Atherosclerosis. 2014;237(2):748–53.
 7. Yip SP. Sequence variation at the human ABO locus. Ann Hum Genet. 
2002;66(Pt 1):1–27.
 8. Ewald DR, Sumner SC. Blood type biochemistry and human disease. 
Wiley Interdiscip Rev Syst Biol Med. 2016;8(6):517–35.
 9. Paré G, Chasman DI, Kellogg M, Zee RY, Rifai N, Badola S, et al. Novel 
association of ABO histo‑blood group antigen with soluble ICAM‑1: 
Page 9 of 9Parente et al. Cardiovasc Diabetol           (2020) 19:68  
results of a genome‑wide association study of 6,578 women. PLoS Genet. 
2008;4(7):e1000118.
 10. Cheung KL, Bouchard BA, Cushman M. Venous thromboembolism, factor 
VIII and chronic kidney disease. Thromb Res. 2018;170:10–9.
 11. Biswas S, Ghoshal PK, Halder B, Mandal N. Distribution of ABO blood 
group and major cardiovascular risk factors with coronary heart disease. 
Biomed Res Int. 2013;2013:782941.
 12. Harjutsalo V, Maric‑Bilkan C, Forsblom C, Groop PH. Impact of sex and age 
at onset of diabetes on mortality from ischemic heart disease in patients 
with type 1 diabetes. Diabetes Care. 2014;37(1):144–8.
 13. Ortiz F, Harjutsalo V, Helantera I, Lempinen M, Forsblom C, Groop PH. 
Long‑term mortality after kidney transplantation in a nationwide 
cohort of patients with type 1 diabetes in Finland. Diabetes Care. 
2019;42(1):55–61.
 14. Harjutsalo V, Thomas MC, Forsblom C, Groop PH, Group FS. Risk of 
coronary artery disease and stroke according to sex and presence 
of diabetic nephropathy in type 1 diabetes. Diabetes Obes Metab. 
2018;20(12):2759–67.
 15. Groop PH, Thomas M, Feodoroff M, Forsblom C, Harjutsalo V, Group FS. 
Excess mortality in patients with type 1 diabetes without albuminuria‑
separating the contribution of early and late risks. Diabetes Care. 
2018;41(4):748–54.
 16. Trégouët DA, Heath S, Saut N, Biron‑Andreani C, Schved JF, Pernod G, 
et al. Common susceptibility alleles are unlikely to contribute as strongly 
as the FV and ABO loci to VTE risk: results from a GWAS approach. Blood. 
2009;113(21):5298–303.
 17. Yamamoto F, McNeill PD, Hakomori S. Human histo‑blood group A2 
transferase coded by A2 allele, one of the A subtypes, is characterized by 
a single base deletion in the coding sequence, which results in an addi‑
tional domain at the carboxyl terminal. Biochem Biophys Res Commun. 
1992;187(1):366–74.
 18. Parmar AS, Alakulppi N, Paavola‑Sakki P, Kurppa K, Halme L, Färkkilä 
M, et al. Association study of FUT2 (rs601338) with celiac disease and 
inflammatory bowel disease in the Finnish population. Tissue Antigens. 
2012;80(6):488–93.
 19. Salem RM, Todd JN, Sandholm N, Cole JB, Chen WM, Andrews D, et al. 
Genome‑wide association study of diabetic kidney disease highlights 
biology involved in glomerular basement membrane collagen. J Am Soc 
Nephrol. 2019;30(10):2000–16.
 20. Marie D, Sow MS, Diack A, Dia K, Mboup MC, Fall PD, Fall MD, et al. Cardio‑
vascular disease and ABO blood‑groups in Africans. Are blood‑group A 
individuals at higher risk of ischemic disease?: A pilot study. Egypt Heart J. 
2017;69(4):229–34.
 21. Blais C, Germain M, Delage G, Grégoire Y. The association between blood 
group and the risk of vascular disease in Quebec blood donors. Blood 
Transfus. 2016;14(5):455–9.
 22. Capuzzo E, Bonfanti C, Frattini F, Montorsi P, Turdo R, Previdi MG, et al. 
The relationship between ABO blood group and cardiovascular disease: 
results from the cardiorisk program. Ann Transl Med. 2016;4(10):189.
 23. Vasan SK, Rostgaard K, Majeed A, Ullum H, Titlestad KE, Pedersen OB, et al. 
ABO blood group and risk of thromboembolic and arterial disease: a 
study of 1.5 million blood donors. Circulation. 2016;133(15):1449–57.
 24. Medalie JH, Levene C, Papier C, Goldbourt U, Dreyfuss F, Oron D, et al. 
Blood groups, myocardial infarction and angina pectoris among 10,000 
adult males. N Engl J Med. 1971;285(24):1348–53.
 25. Barbalic M, Dupuis J, Dehghan A, Bis JC, Hoogeveen RC, Schnabel RB, 
et al. Large‑scale genomic studies reveal central role of ABO in sP‑selectin 
and sICAM‑1 levels. Hum Mol Genet. 2010;19(9):1863–72.
 26. Ferrer‑Admetlla A, Sikora M, Laayouni H, Esteve A, Roubinet F, Blancher A, 
et al. A natural history of FUT2 polymorphism in humans. Mol Biol Evol. 
2009;26(9):1993–2003.
 27. Rosenfeld ME, Campbell LA. Pathogens and atherosclerosis: update on 
the potential contribution of multiple infectious organisms to the patho‑
genesis of atherosclerosis. Thromb Haemost. 2011;106(5):858–67.
 28. Corrales‑Medina VF, Madjid M, Musher DM. Role of acute infection in trig‑
gering acute coronary syndromes. Lancet Infect Dis. 2010;10(2):83–92.
 29. Simonsen JR, Harjutsalo V, Järvinen A, Kirveskari J, Forsblom C, Groop 
PH, et al. Bacterial infections in patients with type 1 diabetes: a 14‑year 
follow‑up study. BMJ Open Diabetes Res Care. 2015;3(1):e000067.
 30. Chen Y, Chen C, Ke X, Xiong L, Shi Y, Li J, et al. Analysis of circulating cho‑
lesterol levels as a mediator of an association between ABO blood group 
and coronary heart disease. Circ Cardiovasc Genet. 2014;7(1):43–8.
 31. Gourgari E, Ma J, Playford MP, Mehta NN, Goldman R, Remaley AT, et al. 
Proteomic alterations of HDL in youth with type 1 diabetes and their 
associations with glycemic control: a case‑control study. Cardiovasc 
Diabetol. 2019;18(1):43.
 32. Svanteson M, Holte KB, Haig Y, Kløw NE, Berg TJ. Coronary plaque charac‑
teristics and epicardial fat tissue in long term survivors of type 1 diabetes 
identified by coronary computed tomography angiography. Cardiovasc 
Diabetol. 2019;18(1):58.
 33. Song J, Chen F, Campos M, Bolgiano D, Houck K, Chambless LE, et al. 
Quantitative influence of ABO blood groups on factor VIII and its ratio to 
von willebrand factor, novel observations from an ARIC study of 11,673 
subjects. PLoS ONE. 2015;10(8):e0132626.
 34. Celik H, Duzenli U, Aslan M, Altiparmak IH, Kirmit A, Kara E, et al. The 
relationship between platelet indices and ABO blood groups in healthy 
adults. J Clin Lab Anal. 2019;33(3):e22720.
 35. Karakas M, Baumert J, Kleber ME, Thorand B, Dallmeier D, Silbernagel G, 
et al. A variant in the ABO gene explains the variation in soluble E‑selectin 
levels‑results from dense genotyping in two independent populations. 
PLoS ONE. 2012;7(12):e51441.
 36. Paterson AD, Lopes‑Virella MF, Waggott D, Boright AP, Hosseini SM, Carter 
RE, et al. Genome‑wide association identifies the ABO blood group as a 
major locus associated with serum levels of soluble E‑selectin. Arterio‑
scler Thromb Vasc Biol. 2009;29(11):1958–67.
 37. Wittemans LBL, Lotta LA, Oliver‑Williams C, Stewart ID, Surendran P, 
Karthikeyan S, et al. Assessing the causal association of glycine with risk 
of cardio‑metabolic diseases. Nat Commun. 2019;10(1):1060.
 38. Ding Y, Svingen GF, Pedersen ER, Gregory JF, Ueland PM, Tell GS, et al. 
Plasma glycine and risk of acute myocardial infarction in patients with 
suspected stable angina pectoris. J Am Heart Assoc. 2015;5(1):e002621.
 39. Pike MM, Larson NB, Wassel CL, Cohoon KP, Tsai MY, Pankow JS, et al. 
ABO blood group is associated with peripheral arterial disease in African 
Americans: the multi‑ethnic study of atherosclerosis (MESA). Thromb Res. 
2017;153:1–6.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub‑
lished maps and institutional affiliations.
